Basics Aclaris Therapeutics, Inc. Aclaris Therapeutics Inc is a clinical-stage specialty pharmaceutical company which focuses on identifying, developing and commercializing differentiated drugs to address significant unmet needs in dermatology. IPO Date: October 7, 2015 Sector: Healthcare Industry: Biotech Market Cap: $227.5M Activated in VL: True Average Daily Range Avg Daily Range: $0.35 | 3.17% Avg Daily Range (30 D): $0.04 | 2.58% Avg Daily Range (90 D): $0.04 | 2.86% Institutional Daily Volume Avg Daily Volume: .67M Avg Daily Volume (30 D): .99M Avg Daily Volume (90 D): .76M Trade Size Avg Trade Size (Sh.): 152 Avg Trade Size (Sh.) (30 D): 192 Avg Trade Size (Sh.) (90 D): 171 Institutional Trades Total Inst.Trades: 1,166 Avg Inst. Trade: $1.57M Avg Inst. Trade (30 D): $4.47M Avg Inst. Trade (90 D): $4.47M Avg Inst. Trade Volume: .14M Avg Inst. Trades (Per Day): 1 Market Closing Trades Avg Closing Trade: $1.5M Avg Closing Trade (30 D): $10.84M Avg Closing Trade (90 D): $10.84M Avg Closing Volume: 142.04K     News Aug 27, 2025 @ 12:00 PM Aclaris Therapeutics to Participate in Two Septemb... Source: Will Roberts May 9, 2025 @ 11:00 AM Aclaris Therapeutics to Participate in the HC Wain... Source: N/A Apr 29, 2025 @ 11:00 AM Aclaris Therapeutics Appoints Jesse Hall, M.D. as ... Source: N/A Mar 3, 2025 @ 6:00 PM JAK Inhibitors Clinical Trial Pipeline Appears Rob... Source: Delveinsight Sep 10, 2024 @ 11:00 AM Aclaris Therapeutics to Participate in the 2024 Ca... Source: N/A Financials   TTM Q2 2025 Q1 2025 Basic EPS $-1.57 $-.13 $-.12 Diluted EPS $-1.57 $-.13 $-.12 Revenue $ 16.79M $ 1.78M $ 1.46M Gross Profit $ 14.41M $ 1.26M $ .95M Net Income / Loss $ -134.65M $ -15.43M $ -15.09M Operating Income / Loss $ -146.64M $ -18.41M $ -18.08M Cost of Revenue $ 2.38M $ .52M $ .51M Net Cash Flow $ 2.57M $ -4.96M $ 5.79M PE Ratio